Title:
COMPLEX OF ANTI-IL-4R ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/135441
Kind Code:
A1
Abstract:
Provided are a complex of an anti-IL-4R antibody or an antigen-binding fragment thereof, and a medical use thereof. Specifically, provided are a complex of an antibody that specifically binds to IL-4R or an antigen-binding fragment thereof covalently linked to a toxin, a pharmaceutical composition comprising the complex, and a use thereof in the preparation of a drug for treating IL-4R-mediated diseases or disorders, especially a use in the preparation of an anti-cancer drug.
Inventors:
WANG HUAN (CN)
LIN YUAN (CN)
TANG YUCHENG (CN)
KE KE (CN)
LIN KAN (CN)
LIAO CHENG (CN)
LIN YUAN (CN)
TANG YUCHENG (CN)
KE KE (CN)
LIN KAN (CN)
LIAO CHENG (CN)
Application Number:
PCT/CN2021/140310
Publication Date:
June 30, 2022
Filing Date:
December 22, 2021
Export Citation:
Assignee:
JIANGSU HENGRUI MEDICINE CO (CN)
SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN)
SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K19/00; A61P35/00; C07K16/30; C12N15/62
Domestic Patent References:
| WO2020038454A1 | 2020-02-27 | |||
| WO1995027732A2 | 1995-10-19 | |||
| WO2010053751A1 | 2010-05-14 | |||
| WO2001092340A2 | 2001-12-06 | |||
| WO2008054606A2 | 2008-05-08 | |||
| WO2014031610A1 | 2014-02-27 | |||
| WO2020038454A1 | 2020-02-27 | |||
| WO2015188934A1 | 2015-12-17 | |||
| WO2014124227A1 | 2014-08-14 | |||
| WO2018217227A1 | 2018-11-29 | |||
| WO2020038454A1 | 2020-02-27 | |||
| WO2020038454A1 | 2020-02-27 |
Foreign References:
| US5635599A | 1997-06-03 | |||
| CN102153655A | 2011-08-17 | |||
| CN102197052A | 2011-09-21 | |||
| EP2954933A1 | 2015-12-16 | |||
| CN202011529235A | 2020-12-22 | |||
| US4892827A | 1990-01-09 | |||
| US5512658A | 1996-04-30 | |||
| US5602095A | 1997-02-11 | |||
| US5608039A | 1997-03-04 | |||
| US5821238A | 1998-10-13 | |||
| US5854044A | 1998-12-29 | |||
| US8871906B2 | 2014-10-28 | |||
| US8907060B2 | 2014-12-09 | |||
| US8936792B2 | 2015-01-20 | |||
| US9346859B2 | 2016-05-24 | |||
| US9206240B2 | 2015-12-08 | |||
| US9388222B2 | 2016-07-12 | |||
| CN103739711A | 2014-04-23 |
Other References:
ALLAHYARI HOSSEIN, ET AL.: "Immunotoxin: A New Tool for Cancer Therapy", TUMOR BIOLOGY, vol. 39, no. 2, 28 February 2017 (2017-02-28), pages 1 - 11, XP055944527, DOI: 10.1177/1010428317692226
LI, MENG ET AL.: "Clinical Targeting Recombinant Immunotoxins for Cancer Therapy", ONCOTARGETS AND THERAPY, vol. 10, 20 July 2017 (2017-07-20), pages 3645 - 3665, XP055526991, DOI: 10.2147/OTT.S134584
JOHANNES, L. ET AL.: "Protein Toxins: Intracellular Trafficking for Targeted Therapy", GENE THERAPY, vol. 12, 19 May 2005 (2005-05-19), pages 1360 - 1368, XP037772410, DOI: 10.1038/sj.gt.3302557
ZHANG YUJIAN, ET AL.: "Fusion Protein of Interleukin4and Pseudomonas Exotoxin with High Cytotoxicity to Cancer Cells ", CHINESE JOURNAL OF BIOTECHNOLOGY, vol. 20, no. 6, 30 November 2004 (2004-11-30), pages 862 - 867, XP055944532, DOI: 10.13345/j.cjb.2004.06.012
BIOCHEM. J., vol. 307, 1995, pages 29 - 37
CANCER RESEARCH, vol. 55, 1 August 1995 (1995-08-01), pages 3357 - 3363
"China Tumor Clinical Yearbook", July 2010, PEKING UNION MEDICAL COLLEGE PRESS, pages: 61
"Biotechnological Pharmaceutics", January 2016, CHINA MEDICAL SCIENCE PRESS, pages: 209 - 211
"The three-letter and single-letter codes for amino acids used in the present disclosure are described", J. BIOL. CHEM, vol. 243, 1968, pages 3558
HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
ALFTHAN ET AL., PROTEIN ENG., vol. 8, 1995, pages 725 - 731
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106
HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
LI, MENG ET AL.: "Clinical Targeting Recombinant Immunotoxins for Cancer Therapy", ONCOTARGETS AND THERAPY, vol. 10, 20 July 2017 (2017-07-20), pages 3645 - 3665, XP055526991, DOI: 10.2147/OTT.S134584
JOHANNES, L. ET AL.: "Protein Toxins: Intracellular Trafficking for Targeted Therapy", GENE THERAPY, vol. 12, 19 May 2005 (2005-05-19), pages 1360 - 1368, XP037772410, DOI: 10.1038/sj.gt.3302557
ZHANG YUJIAN, ET AL.: "Fusion Protein of Interleukin4and Pseudomonas Exotoxin with High Cytotoxicity to Cancer Cells ", CHINESE JOURNAL OF BIOTECHNOLOGY, vol. 20, no. 6, 30 November 2004 (2004-11-30), pages 862 - 867, XP055944532, DOI: 10.13345/j.cjb.2004.06.012
BIOCHEM. J., vol. 307, 1995, pages 29 - 37
CANCER RESEARCH, vol. 55, 1 August 1995 (1995-08-01), pages 3357 - 3363
"China Tumor Clinical Yearbook", July 2010, PEKING UNION MEDICAL COLLEGE PRESS, pages: 61
"Biotechnological Pharmaceutics", January 2016, CHINA MEDICAL SCIENCE PRESS, pages: 209 - 211
"The three-letter and single-letter codes for amino acids used in the present disclosure are described", J. BIOL. CHEM, vol. 243, 1968, pages 3558
HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
ALFTHAN ET AL., PROTEIN ENG., vol. 8, 1995, pages 725 - 731
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106
HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
Attorney, Agent or Firm:
GE CHENG & CO., LTD (CN)
Download PDF: